Government pledges £20 million to develop new coronavirus vaccine

The Government has today pledged £20 million to develop a new coronavirus vaccine following concerns over the ongoing outbreak in China

The funding will go to the Coalition for Epidemic Preparedness Innovations (CEPI) – a global partnership between public, private, philanthropic, and civil society organisations launched to develop vaccines to stop future epidemics.

It will support the work of three new programmes to develop vaccines against the novel coronavirus, 2019-nCoV with the aim to advance vaccine candidates into clinical testing as soon as possible.

Dr Richard Hatchett, CEO of CEPI, said:

“CEPI welcomes the UK’s continued support and funding for our vital work, which comes at a crucial moment as the world races to respond to the emergence of a novel coronavirus. The rapid global spread and unique epidemiological characteristics of the virus are deeply concerning.

“Our hope is that, with our partners, we can get an investigational vaccine from gene sequencing of the pathogen through to clinical testing in 16 weeks. The earliest stage of clinical trials (Phase I), to establish the safety of investigational vaccines, would take around two to four months.

“This is an extremely ambitious timeline – indeed, it would be unprecedented in the of field vaccine development. It is important to remember that even if we are successful – and there can be no guarantee – there will be further challenges to navigate before we can make vaccines more broadly available.”

Health Secretary Matt Hancock said:

“Vaccines are our best defence against a host of deadly diseases, including coronavirus. The UK is a hub of world-leading and pioneering research, and it is vital that we lead the way in developing new vaccines to target global threats with scientists from across the world.

“The £20 million announced today will help our globally recognised vaccine development capabilities continue to develop new defences against emerging diseases including coronavirus. It’s paramount we invest in vital research about infectious diseases, keeping the UK at the forefront of modern-day science so we can share this knowledge globally.”